Phaseline

Targets › CAMPT

CAMPT: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CAMPT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TaiRxTRX-920 Oral Gel
Topoisomerase I inhibitor (SN38, active metabolite of irinotecan)
CAMPTPhase 1Advanced Solid TumorDec 2026

Conditions

Advanced Solid Tumor (1)

Modalities

small molecule (1)

Companies

TaiRx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.